Article
Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients
Registro en:
FERREIRA, Helen et al. Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients. Frontiers in Immunology, v. 12, Article 662307, p. 1 - 10, July 2021.
1664-3224
10.3389/fimmu.2021.662307
Autor
Ferreira, Helen
Mendes, Mayara Abud
Barbosa, Mayara Garcia de Mattos
Oliveira, Eliane Barbosa de
Sales, Anna Maria
Moraes, Milton Ozório
Sarno, Euzenir Nunes
PInheiro, Roberta Olmo
Resumen
The treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises
12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have
described the immunological phenotypic pattern in skin lesions in multibacillary patients.
Here, we evaluated the effect of MDT on skin cell phenotype and on the Mycobacterium
leprae-specific immune response. An analysis of skin cell phenotype demonstrated a
significant decrease in MRS1 (SR-A), CXCL10 (IP-10) and IFNG (IFN-g) gene and protein
expression after MDT release. Patients were randomized according to whether they
experienced a reduction in bacillary load after MDT. A reduction in CXCL10 (IP-10) in sera
was associated with the absence of a reduction in the bacillary load at release. Although
IFN-g production in response to M. leprae was not affected by MDT, CXCL10 (IP-10) levels
in response to M. leprae increased in cells from patients who experienced a reduction in
bacillary load after treatment. Together, our results suggest that CXCL10 (IP-10) may be a
good marker for monitoring treatment efficacy in multibacillary patients.